US2006234286A1PendingUtilityA1

Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses

54
Assignee: NORTHWEST BIOTHERAPEUTICS INCPriority: Mar 16, 2000Filed: May 22, 2006Published: Oct 19, 2006
Est. expiryMar 16, 2020(expired)· nominal 20-yr term from priority
Inventors:Yaling Zhou
A61K 48/00C07K 14/4703A61K 38/00A61P 35/00A61K 39/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the discovery, identification and characterization of a novel tumor suppressor gene designated PARIS-1. The invention includes nucleotide sequences of the PARIS-1 gene and amino acid sequences of its encoded protein product(s), as well as fragments, derivatives and analogs thereof. The invention also includes the production of PARIS-1 proteins, fragments and derivatives and of antibodies specific for PARIS-1 gene products. The invention further comprises agents and compositions which can modulate the expression of PARIS-1 or PARIS-1 expression products to effect the proliferation of cells which express PARIS-1. One particular embodiment comprises agents and compounds which can slow or ablate the proliferation of prostate tumor cells.

Claims

exact text as granted — not AI-modified
1 . An antibody which can immunospecifically bind a PARIS-1 protein or fragment thereof.  
     
     
         2 . The antibody of  claim 1  which is a monoclonal antibody.  
     
     
         3 . A composition comprising an amount of PARIS-1 protein, or a fragment thereof, which can effectively modulate cell proliferation and a pharmaceutically acceptable carrier.  
     
     
         4 . The composition of  claim 3 , wherein the PARIS-1 protein is human PARIS-1  
     
     
         5 . A composition comprising an amount of an antigen binding fragment or derivative of an antibody immunospecific for PARIS-1 protein and a pharmaceutically acceptable carrier.  
     
     
         6 . A method for decreasing the rate of proliferation of a cell which expresses PARIS-1 in a subject comprising administering an amount of an agent which effectively modulates PARIS-1 activity to modulate cell proliferation.  
     
     
         7 . The method of  claim 6 , wherein the agent promotes translation of mRNA transcripts which encode PARIS-1.  
     
     
         8 . The method of  claim 6 , wherein the agent comprises a nucleic acid encoding a PARIS-1 protein, a nucleic acid encoding a PARIS-1 derivative or analog that is active in inhibiting cell proliferation.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.